Thomas Treharne Warner

Thomas Treharne Warner

Auto-generated profile, based on publicly available information

Thomas Treharne Warner

Queen Square Brain Bank for Neurological Disorders, University College London Queen Square Institute of Neurology, University College London, London, UK

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in The Lancet
Verified
Journal Article
Closed access
DADilan Athauda
Dilan Athauda
KMKate Maclagan
Kate Maclagan
SSSimon S Skene
Simon S Skene
MBMartha Bajwa-Joseph
Martha Bajwa-Joseph
DLDawn Letchford
Dawn Letchford
TFThomas Foltynie
Thomas Foltynie

15 September 2022 in Nature
Verified
Journal Article
Open access
PDF file
YYYang Yang
Yang Yang
YSYang Shi
Yang Shi
MSManuel Schweighauser
Manuel Schweighauser
XZXianjun Zhang
Xianjun Zhang
AKAbhay Kotecha
Abhay Kotecha
MGMichel Goedert
Michel Goedert
Parkinson’s disease (PD) is the most common movement disorder, with resting tremor, rigidity, bradykinesia and postural instability being major symptoms1. Neuropathologically, it is characterized by the presence of abundant filamentous inclusions of α-synuclein in the form of Lewy bodies and Lewy neurites in some brain cells, including dopaminergic nerve cells of the substantia nigra2. PD is increasingly recognised as a multisystem disorder, with cognitive decline being one of its most common non-motor symptoms. Many patients with PD develop dementia more than 10 years after diagnosis3. PD dementia (PDD) is clinically and neuropathologically similar to dementia with Lewy bodies (DLB), which is diagnosed when cognitive impairment precedes parkinsonian motor signs or begins within one year from their onset4. In PDD, cognitive impairment develops in the setting of well-established PD. Besides PD and DLB, multiple system atrophy (MSA) is the third major synucleinopathy5. It is characterized by the presence of abundant filamentous α-synuclein inclusions in brain cells, especially oligodendrocytes (Papp-Lantos bodies). We previously reported the electron cryo-microscopy structures of two types of α-synuclein filament extracted from the brains of individuals with MSA6. Each filament type is made of two different protofilaments. Here we report that the cryo-electron microscopy structures of α-synuclein filaments from the brains of individuals with PD, PDD and DLB are made of a single protofilament (Lewy fold) that is markedly different from the protofilaments of MSA. These findings establish the existence of distinct molecular conformers of assembled α-synuclein in neurodegenerative disease.

1 December 2008 in The Lancet Neurology
Verified
Journal Article
Closed access
SSSara Salinas
Sara Salinas
CPChristos Proukakis
Christos Proukakis
ACAndrew Crosby
Andrew Crosby
TWThomas T Warner
Thomas T Warner

22 February 2004 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CWChristian Windpassinger
Christian Windpassinger
MAMichaela Auer-Grumbach
Michaela Auer-Grumbach
JIJoy Irobi
Joy Irobi
HPHeema Patel
Heema Patel
EPErwin Petek
Erwin Petek
KWKlaus Wagner
Klaus Wagner
Distal hereditary motor neuropathy (dHMN) or distal spinal muscular atrophy (OMIM #182960) is a heterogeneous group of disorders characterized by an almost exclusive degeneration of motor nerve fibers, predominantly in the distal part of the limbs1. Silver syndrome (OMIM #270685) is a rare form of hereditary spastic paraparesis mapped to chromosome 11q12–q14 (SPG17) in which spasticity of the legs is accompanied by amyotrophy of the hands and occasionally also the lower limbs2,3. Silver syndrome and most forms of dHMN are autosomal dominantly inherited with incomplete penetrance and a broad variability in clinical expression. A genome-wide scan in an Austrian family with dHMN-V (ref. 4) showed linkage to the locus SPG17, which was confirmed in 16 additional families with a phenotype characteristic of dHMN or Silver syndrome. After refining the critical region to 1 Mb, we sequenced the gene Berardinelli-Seip congenital lipodystrophy (BSCL2) and identified two heterozygous missense mutations resulting in the amino acid substitutions N88S and S90L. Null mutations in BSCL2, which encodes the protein seipin, were previously shown to be associated with autosomal recessive Berardinelli-Seip congenital lipodystrophy5 (OMIM #269700). We show that seipin is an integral membrane protein of the endoplasmic reticulum (ER). The amino acid substitutions N88S and S90L affect glycosylation of seipin and result in aggregate formation leading to neurodegeneration.

1 April 2019 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
EPEduardo De Pablo-Fernández
Eduardo De Pablo-Fernández
ALAndrew J. Lees
Andrew J. Lees
JHJanice L. Holton
Janice L. Holton
TWThomas T. Warner
Thomas T. Warner
Importance Clinical subtyping of Parkinson disease at diagnosis is useful in estimating disease course and survival. Severity and rate of progression of neuropathologies are important determinants of clinical Parkinson subtypes. Objective To provide longitudinal clinical disease-course data and neuropathologic correlation for newly proposed Parkinson disease subtypes. Design, Setting, and Participants Retrospective cohort study of consecutive patients with autopsy-confirmed Parkinson disease who were regularly seen throughout their disease course by hospital specialists in the United Kingdom and donated their brain at death to the Queen Square Brain Bank between January 2009 and December 2017. Patients with additional neuropathologic diagnoses, monogenic forms of parkinsonism, or insufficiently detailed clinical information were excluded. Based on severity of motor symptoms, rapid eye movement sleep behavior disorder, and autonomic and cognitive function at diagnosis, patients were classified adapting a subtyping classification into mild-motor predominant, intermediate, or diffuse malignant subtypes. Main Outcomes and Measures Time from diagnosis to disease milestones (recurrent falls, wheelchair dependence, dementia, and care home placement) and death were compared between subtypes, and their risk was estimated using Cox hazard regression models. Severity and distribution of Lewy pathology and Alzheimer disease–related pathology were assessed using staging systems. Results From a total of 146 patients, 111 patients were included (67 men [60.4%]; mean [SD] age at diagnosis, 62.5 [11.5] years). The diffuse malignant subtype had earlier development of milestones and reduced survival. Cox proportional hazard regression showed an increased adjusted risk of any disease milestone (hazard ratio, 10.90; 95% CI, 5.51-21.58;P < .001) and death (hazard ratio, 3.65; 95% CI, 1.98-6.75;P < .001) in the diffuse malignant group. Age at diagnosis was the only additional variable with statistical significance (adjusted hazard ratio for death, 1.14; 95% CI, 1.11-1.17; P <.001). Staging of Lewy pathology and Alzheimer disease–related pathology did not differ between subtypes, although they showed different rates of progression, and the latter was associated with age at death. Conclusions and Relevance Parkinson clinical subtypes at diagnosis may estimate disease course and survival, which may be useful in providing a more accurate prognosis in individual patients in clinical practice and helping to stratify subgroups in clinical trials. Different severity and progression of neuropathologies are important determinants of Parkinson subtypes, and age at diagnosis should be included in future subtype classifications.

24 March 2003 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
TWThomas T. Warner
Thomas T. Warner
ASAnthony Schapira
Anthony Schapira